Quantcast
Last updated on April 24, 2014 at 13:10 EDT

Latest tumor Stories

2013-12-17 08:29:11

Latest Award Further Demonstrates Company's Established International Intellectual Property Position IRVING, Texas, Dec. 17, 2013 /PRNewswire/ -- Caris Life Sciences(®), a leading biosciences company focused on fulfilling the promise of personalized medicine, has been granted a patent in The People's Republic of China covering its molecular profiling service, Caris Molecular Intelligence(TM), for cancer patients. China represents a large population of unmet medical need, with...

2013-12-13 23:01:59

An analysis by ECOG-ACRIN researchers shows that TILs are a prognostic factor in women with triple negative breast cancer. San Antonio, TX (PRWEB) December 13, 2013 An analysis presented by researchers from the ECOG-ACRIN Cancer Research Group this week at the San Antonio Breast Cancer Symposium showed that stromal tumor-infiltrating lymphocytes (TILs) represent a robust prognostic factor in patients with triple-negative breast cancer (TNBC) who are treated with standard adjuvant...

2013-12-13 09:38:35

More than one third of younger, early stage breast cancer patients undergo unnecessary imaging procedures – including position emission tomography (PET), computed tomography (CT), nuclear medicine bone scans (NMBS) and tumor markers (TM) -- at the time of staging and diagnosis, according to research from The University of Texas MD Anderson Cancer Center. Presented at a poster session at the 2013 CTRC-AACR San Antonio Breast Cancer Symposium by Carlos Barcenas, M.D., assistant professor...

2013-12-12 20:24:56

Mutational status and protein analysis both key to better understanding possible treatment implications for difficult-to-treat disease IRVING, Texas, Dec. 12, 2013 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, presented a breast cancer study at the 2013 CTCR-AACR San Antonio Breast Cancer Symposium held this week in San Antonio, Texas. The analysis focuses on identifying potentially actionable therapeutic...

2013-12-12 08:31:14

Calithera Identifies Potential Biomarkers for Selecting Breast Cancer Tumors with High Sensitivity to CB-839 Glutaminase Inhibition SOUTH SAN FRANCISCO, Calif., Dec. 12, 2013 /PRNewswire/ -- Calithera Biosciences, a biotechnology company focused on the development of novel cancer therapeutics, today announced the presentation of preclinical data for its lead anti-cancer therapeutic candidate, CB-839, at the 2013 San Antonio Breast Cancer Symposium. CB-839 is a potent,...

2013-12-11 12:57:14

They have discovered how the anti-tumor activity of immune cells can be restored The Leuven-based VIB researchers have revealed a mechanism that explains why the anti-tumor activity of specific immune cells called macrophages is suppressed during tumor growth. They have also demonstrated that blocking the protein Nrp1 can restore this anti-tumor immune response. This is a first. Nrp1 may provide an important hub for the development of new therapies against cancer. Max Mazzone: "For many...

2013-12-10 23:02:39

Study shows small number of tumor mutations drive tumor growth. Only with this information, can the application of inhibitor drugs be truly targeted and effective. (PRWEB) December 10, 2013 Recent cancer research from the Program for Evolutionary Dynamics at Harvard University, under the direction of Martin Nowak and mathematics graduate student Ivan Bozic PhD, has shown that only a small percentage of a tumor’s mutations drive tumor growth. The study reveals the critical necessity of...

2013-12-10 10:35:18

Washington University Pediatric Cancer Genome Project study identifies drugs that enhance oxidative stress as possible weapon against most common pediatric soft tissue tumor Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle and other soft tissue. The findings are the latest from the St. Jude Children’s Research...

2013-12-10 08:30:53

CB-839 Demonstrates In Vitro and In Vivo Activity Against Hematologic Malignancies SOUTH SAN FRANCISCO, Calif., Dec. 10, 2013 /PRNewswire/ -- Calithera Biosciences, a biotechnology company focused on the development of novel cancer therapeutics, today announced the presentation of preclinical data for its lead anti-cancer therapeutic candidate, CB-839, at the 55(th) American Society of Hematology (ASH) Annual Meeting. CB-839 is a potent, selective, orally available glutaminase...

2013-12-09 23:01:32

St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project study identifies drugs that enhance oxidative stress as possible weapon against most common pediatric soft tissue tumor Memphis, Tenn. (PRWEB) December 09, 2013 Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle and other...